{"entity":{"id":"paper-ranganathan-lancet-oncol","kind":"paper","name":"The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research","aka":[],"tldr":"Paper cited by one institution page, indexed on Europe PMC as PubMed record 34216541 and published in The Lancet Oncology; the citing page links this DOI, which is how the record was matched.","summary":"Low-income and middle-income countries (LMICs) have a disproportionately high burden of cancer and cancer mortality. The unique barriers to optimum cancer care in these regions necessitate context-specific research. The conduct of research in LMICs has several challenges, not least of which is a paucity of formal training in research methods. Building capacity by training early career researchers is essential to improve research output and cancer outcomes in LMICs. The International Collaboration for Research methods Development in Oncology (CReDO) workshop is an initiative by the Tata Memorial Centre and the National Cancer Grid of India to address gaps in research training and increase capacity in oncology research. Since 2015, there have been five CReDO workshops, which have trained more than 250 oncologists from India and other countries in clinical research methods and protocol development. Participants from all oncology and allied fields were represented at these workshops. Protocols developed included clinical trials, comparative effectiveness studies, health services research, and observational studies, and many of these protocols were particularly relevant to cancer management in LMICs. A follow-up of these participants in 2020 elicited an 88% response rate and showed that 42% of participants had made progress with their CReDO protocols, and 73% had initiated other research protocols and published papers. In this Policy Review, we describe the challenges to research in LMICs, as well as the evolution, structure, and impact of CReDO and other similar workshops on global oncology research.\n\nIndexed on Europe PMC as PubMed record 34216541 (DOI 10.1016/s1470-2045(21)00077-2). Matched by DOI alone: one institution page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Lancet Oncol 2021","url":"https://doi.org/10.1016/s1470-2045(21)00077-2"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/34216541/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/34216541"}],"tags":["europepmc-ingest"],"related":["national-cancer-grid"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2021,"doi":"10.1016/s1470-2045(21)00077-2","pmid":"34216541","authors":"Ranganathan P, Chinnaswamy G, Sengar M, et al.","paperType":"review","findings":[],"whatItMeans":"One institution page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.","caveats":["Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-ranganathan-lancet-oncol/","neighbours":{"institution":[{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","route":"/institutions/national-cancer-grid/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}